Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P H Gumerlock

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
The Prostate|February 11, 1999
Overexpression of cyclin D1 is rare in human prostate carcinomaL M Gumbiner, P H Gumerlock, P C Mack, et al.
Molecular Immunology|December 11, 1999
Critical Lym-1 binding residues on polymorphic HLA-DR moleculesL M Rose, C T Deng, S L Scott, et al.
Chinese Medical Journal|January 5, 2002
Anaerobic bacteria and intrahepatic stones: detections of Clostridium sp. and Bacteroides fragilisY Liu, K Lam, Y J Tang, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 27, 2001
Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapyL A Kroger, G L DeNardo, P H Gumerlock, et al.
Biochemical and Molecular Medicine|December 1, 1996
Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activityS J Freedland, R W Malone, H M Borchers, et al.
Cancer Research|December 1, 1995
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expressionS J DeNardo, P H Gumerlock, M D Winthrop, et al.
Cancer Letters|April 24, 2007
Origin and prognostic value of circulating KRAS mutations in lung cancer patientsO Gautschi, B Huegli, A Ziegler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 20, 1998
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenograftsS J DeNardo, D L Kukis, L A Miers, et al.
Cancer Research|July 1, 1996
CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agarM Nagabhushan, C M Miller, T P Pretlow, et al.
Molecular Endocrinology (Baltimore, Md.)|April 1, 1997
Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cellsJ Tan, Y Sharief, K G Hamil, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
The Prostate|February 11, 1999
Overexpression of cyclin D1 is rare in human prostate carcinomaL M Gumbiner, P H Gumerlock, P C Mack, et al.
Molecular Immunology|December 11, 1999
Critical Lym-1 binding residues on polymorphic HLA-DR moleculesL M Rose, C T Deng, S L Scott, et al.
Chinese Medical Journal|January 5, 2002
Anaerobic bacteria and intrahepatic stones: detections of Clostridium sp. and Bacteroides fragilisY Liu, K Lam, Y J Tang, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 27, 2001
Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapyL A Kroger, G L DeNardo, P H Gumerlock, et al.
Biochemical and Molecular Medicine|December 1, 1996
Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activityS J Freedland, R W Malone, H M Borchers, et al.
Cancer Research|December 1, 1995
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expressionS J DeNardo, P H Gumerlock, M D Winthrop, et al.
Cancer Letters|April 24, 2007
Origin and prognostic value of circulating KRAS mutations in lung cancer patientsO Gautschi, B Huegli, A Ziegler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 20, 1998
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenograftsS J DeNardo, D L Kukis, L A Miers, et al.
Cancer Research|July 1, 1996
CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agarM Nagabhushan, C M Miller, T P Pretlow, et al.
Molecular Endocrinology (Baltimore, Md.)|April 1, 1997
Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cellsJ Tan, Y Sharief, K G Hamil, et al.
Pageof 8